

## DESCRIPTION

|                           |                                                                                                                                                                                                                                                                             |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Species Reactivity</b> | Mouse                                                                                                                                                                                                                                                                       |
| <b>Specificity</b>        | Detects mouse VSIG2 in direct ELISAs and Western blots. In Western blots, approximately 25% cross-reactivity with recombinant human (rh) VSIG2 is observed and less than 10% cross-reactivity with rhVSIG3 is observed.                                                     |
| <b>Source</b>             | Polyclonal Goat IgG                                                                                                                                                                                                                                                         |
| <b>Purification</b>       | Antigen Affinity-purified                                                                                                                                                                                                                                                   |
| <b>Immunogen</b>          | Mouse myeloma cell line NS0-derived recombinant mouse VSIG2<br>Val25-Ala244 (Glu240Asp)<br>Accession # Q9Z109                                                                                                                                                               |
| <b>Conjugate</b>          | Alexa Fluor 594<br>Excitation Wavelength: 590 nm<br>Emission Wavelength: 617 nm                                                                                                                                                                                             |
| <b>Formulation</b>        | Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide<br><br>*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions. |

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

**Western Blot** Optimal dilution of this antibody should be experimentally determined.

## PREPARATION AND STORAGE

**Shipping** The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

## BACKGROUND

VSIG2 (V-set and Ig domain-containing protein 2; also CTM and CT-like protein) is presumably a 50-60 kDa member of the CTX family of Ig-Superfamily proteins. It shows expression in stomach and prostate by Northern blot, and likely participates in cell adhesion. Mouse VSIG2 precursor is 328 amino acids (aa) in length. It is a type I transmembrane (glyco)protein that contains a 220 aa extracellular domain (ECD) (aa 25-244) and a 63 aa cytoplasmic region. The ECD contains one V-type (aa 25-138) and one C2-type Ig-like domain (aa 145-234). Over aa 25-244, mouse VSIG2 is 94%, 83% and 85% aa identical to rat, canine and human VSIG2, respectively. Two potential splice variants exist, one that shows a deletion of aa 305-328 and a second that shows a deletion of aa 144-236.

## PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.